Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
about
Deep molecular responses for treatment-free remission in chronic myeloid leukemiaImatinib in chronic myeloid leukemia: an overviewEarly prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaEvolution of acquired resistance to anti-cancer therapy.Clinical and biological predictors of outcome following relapse of CML post-allo-SCTHow we will treat chronic myeloid leukemia in 2016.Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.The role of stem cell transplantation for chronic myelogenous leukemia in the 21st centuryMonitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsHow and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia.The role of early molecular predictor in transplant-eligible chronic myelogenous leukemia.Do we have to kill the last CML cell?Role of allogeneic transplantation in chronic myeloid leukemia.Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.Curing chronic myeloid leukemia.Relapse assessment following allogeneic SCT in patients with MDS and AML.Management of advanced-phase chronic myeloid leukemia.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.Allogeneic transplantation for CML in the TKI era: striking the right balance.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.Bilateral Maxillary, Sphenoid Sinuses and Lumbosacral Spinal Cord Extramedullary Relapse of CML Following Allogeneic Stem Cell Transplant.Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation.How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
P2860
Q26745594-CD3DA4AE-579F-40A1-ABE1-F78C3299AA5CQ26865086-240B7CEE-BC5B-4513-BD27-E88951E76C70Q33632220-D559A67F-D6B3-4148-9637-75EC3B64E05DQ33758382-05D70A23-5345-44DE-AADF-2A243F8D4B87Q35054717-34896349-2EA1-44B6-8189-AF5A26058B3CQ35269378-AB165188-C292-4E44-B080-20AD0322C759Q35633858-28428439-70DB-4C4A-BCF9-D5180FD7C4C8Q35634865-D5E43D0B-1615-4535-9E1C-A2BCB0654A7CQ35849776-A0E3E072-F127-48BE-B891-5454DEF9E336Q35900929-3D160FE0-873D-4B61-BD49-EDEE989C0A95Q35931271-3C4EC583-A7E7-430B-A8A7-B49B614DC38CQ36600934-958694ED-805A-42D4-A069-CDA793D72FC6Q37344050-85A1EC26-D469-4C78-8944-3812FFA069AEQ37511076-07401261-1E8E-484C-A0D8-EA1D5F55F234Q37545067-74B2A7F6-B970-4669-90EE-4DE0F7828232Q37559148-706B4FAA-5F90-4D1D-B6E4-9276ADCF2E69Q37559198-ADA0BE17-6BFC-4440-9016-383250BFC989Q37789148-94CAACDB-698D-4068-A07C-585FDC021EACQ37810113-1C63BC64-E870-44D9-B8B0-62A3F0CE9820Q37832506-3E3B2DD4-2858-44C2-B41C-EB90BA12FD39Q37992839-5854A537-C388-4E23-95C2-825669C0D6B2Q38199623-4EEAE738-8A22-443C-BB3C-184D3CDE5B53Q38452040-6D33D570-9D98-4668-A710-717974584625Q38585916-DD7E0EAC-167D-494A-AE8B-8F0D5D2BBA9BQ38634736-9AE099A1-2D75-45F8-B2EB-24DE37B16305Q38767908-AB230AF0-622E-4CCC-9680-013C566B729BQ38943340-D2942D9E-121E-4DA5-9BB9-1014543354A0Q40648938-16157CE8-7889-4D1A-86E0-6DB242563525Q41538174-2F8DA375-7573-4A4D-AF9C-ED086EB91B6AQ41765680-4F8BF615-BD0A-4B97-A3F0-2E163C973836Q42919964-17938136-2BBE-485A-BF4F-EDEEF439A47EQ43188134-E7943B73-3B35-4457-A99B-F3239E2DDEC4Q48162932-FEEA4D82-F3A2-4D0D-9F14-8A87181A713BQ53004947-6988ECD0-9ED1-43E1-89EC-A60786649E14Q54384266-31F2D024-C9B5-4E51-A1B3-48E9A9282E8DQ57821741-E03DFAAC-584D-48A3-AC7F-01AFF317F871
P2860
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Serial measurement of BCR-ABL ...... ay not require further therapy
@ast
Serial measurement of BCR-ABL ...... ay not require further therapy
@en
type
label
Serial measurement of BCR-ABL ...... ay not require further therapy
@ast
Serial measurement of BCR-ABL ...... ay not require further therapy
@en
prefLabel
Serial measurement of BCR-ABL ...... ay not require further therapy
@ast
Serial measurement of BCR-ABL ...... ay not require further therapy
@en
P2093
P2860
P50
P1433
P1476
Serial measurement of BCR-ABL ...... ay not require further therapy
@en
P2093
David Marin
Derville O'Shea
Eduardo Olavarria
Jamshid S Khorashad
Jane F Apperley
Jaspal Kaeda
John M Goldman
Susan Saunders
P2860
P304
P356
10.1182/BLOOD-2005-08-3320
P407
P577
2006-01-31T00:00:00Z